Cancer Clinical Trials

Cancer Clinical Research - For Patients.

Clinical Trials

Below is the current list of active cancer clinical trials. Click on each heading to reveal more information about each trial.

NSABP B-51/RTOG 1304 - Details...

Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery - Breast

This randomized phase III trial studies standard or comprehensive radiation therapy in treating patients with early-stage breast cancer who have undergone surgery. Radiation therapy uses high-energy x rays to kill tumor cells. It is not yet known whether comprehensive radiation therapy is more effective than standard radiation therapy in treating patients with breast cancer. Elibigibilty includes being at least 18 years old, patient must have clinically T1-3, N1 breast cancer at the time of diagnosis, must have hormone receptors (ER/PR) and HER-2 Neu testing performed on tumor, patient must have completed a minimum of 12 weeks of standard neoadjuvant chemotherapy consisting of an anthracycline and/or taxane-based regimen, for patients who receive adjuvant chemotherapy after surgery, a maximum of 12 weeks of intended chemotherapy may be administered but must be completed before randomization.

RTOG 1119 - Details...

Whole-Brain Radiation Therapy With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer - Breast

This randomized phase II trial studies how well whole-brain radiation therapy (WBRT) with or without lapatinib ditosylate works in treating patients with brain metastasis from HER2-positive breast cancer. Radiation therapy uses high energy x rays to kill tumor cells. Lapatinib ditosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether radiation therapy together with lapatinib ditosylate is an effective treatment for brain metastasis from breast cancer. Eligibiltiy includes being at least 18 years old,

  • Pathologically (histologically or cytologically) proven diagnosis of invasive breast cancer
  • Human epidermal growth factor receptor 2 (HER2)-overexpressing breast cancer (3+ staining by immunohistochemistry or HER2 gene amplification by fluorescent in situ hybridization[FISH] or silver in situ hybridization [SISH] ≥ 2.2)
  • Brain metastases that fulfill 1 of the following:

    • Progressive parenchymal brain metastases following stereotactic radiosurgery for 1-3 brain metastases, with at least 1 new measurable lesion
    • Progressive parenchymal brain metastases following surgical resection of 1-3 brain metastases, as long as at least 1 brain metastasis is measurable

  • At least 14 days between FINAL dose of prior chemotherapy and study entry, with recovery of toxicities to grade 0 or 1
  • No prior whole-brain radiation therapy (WBRT)
  • No prior lapatinib therapy

 

ECOG E1Z11 - Details...

Anastrozole in Treating Aromatase Inhibitor Musculoskeletal Symptoms in Female Patients With Stage I-III Breast Cancer - Breast

This pilot clinical trial studies anastrozole in treating aromatase inhibitor musculoskeletal symptoms in female patients with stage I-III breast cancer. Anastrozole may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Eligibility includes being at least 18 years old,

  • Patients must have estrogen and/or progesterone receptor positive histologically confirmed stage I-III adenocarcinoma of the breast
  • Patients must have completed recommended local therapy and adjuvant chemotherapy for breast cancer
  • Patients must not have received prior AI therapy with exemestane, letrozole, or anastrozole as adjuvant therapy or for prevention of breast cancer; prior tamoxifen as adjuvant therapy or for prevention is allowed
  • Plan to treat with anastrozole for at least 12 months
  • Eastern Cooperative Oncology Group (ECOG) performance status between 0-2
  • Patients must not be currently taking (or have taken in the past 6 months) ongoing, daily analgesic medication for active, chronic conditions (i.e., rheumatoid arthritis, carpal tunnel syndrome, tenosynovitis, systemic lupus erythematosus, gout, fibromyalgia, or severe osteoarthritis involving the hands, wrists, hips, knees, feet or ankles); (note: patients taking daily low dose aspirin are allowed to participate in this trial)
  • Patients must have worst pain rated as less than 4 out of 10 on the following question: "In the past week, how much pain have you had on a scale of 0 to 10, where 0 equals no pain and 10 means the worst pain you can imagine; " NOTE: This question regarding patient's pain should be completed within one week prior to registration; this pain item may be completed orally prior to consent up to 7 days prior to registration; it is not necessary to complete this pain item via the PROMIS website

 

 

RTOG 1005 - Details...

Higher-Dose Radiation Therapy or Standard Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery - Breast

Radiation therapy uses high-energy x rays to kill tumor cells. It is not yet know whether high-dose radiation therapy is more effective than standard radiation therapy in treating breast cancer. This randomized phase III trial studies how well high-dose radiation therapy works compared to standard radiation therapy in treating patients with early-stage breast cancer that was removed by surgery. Eligibility includes being at least 18 years old, stage 0, I or II breast cancer, no metastatic disease and no previous radiation to the breast.

 

NSABP-47 - Details...

Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer - Breast

Drugs used in chemotherapy work in different ways to stop the growth of tumorcells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) and giving chemotherapy after surgery may kill more tumor cells. Monoclonal antibodies, such as trastuzumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. It is not yet known whether combination chemotherapy is more effective with trastuzumab in treating breast cancer. This randomizedphase III clinical trial is studying chemotherapy with or without trastuzumab after surgery to see how well they work in treating women with invasive breast cancer. Eligibity includes being at least 18 years, no metastic disease, HER2-low disease, no previous trastuzmab, chemotherapy, HER2 targeted therapy or whole breast radiation therapy.

 

RTOG 1010 - Details...

Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer - Gastrointestinal Malignancies Stromal Tumors or GE Junction

This randomized phase III trial studies how well radiation therapy, paclitaxel, and carboplatin with or without trastuzumab work in treating patients with esophageal cancer. Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as trastuzumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. It is not yet known whether giving radiation therapy and combination chemotherapy together with or without trastuzumab is more effective in treating esophageal cancer. Eligibility includes being at least 18 years of age, pathologically confirmed primary adenocarcinoma of the esophagus that involves the mid (up to 25 cm), distal, or esophagogastric junction; the cancer may involve the stomach up to 5 cm, an endoscopy with biopsy, intent to submit tissue for central HER2 testing, and stage T1N1-2, T2-3N0-2 disease.

CTSU S1201 - Details...

Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer - Gastrointestinal Malignancies Stromal Tumors or GE Junction

This randomized phase II trial studies how well oxaliplatin, leucovorin calcium, and fluorouracil work compared to irinotecan hydrochloride and docetaxel in treating patients with esophageal cancer, gastric cancer, or gastroesophageal junction cancer. Eligibility includes: being a least 18 years old and

•Patients must have unresectable advanced or metastatic histologically or cytologically confirmed adenocarcinoma of the esophagus, stomach, or gastroesophageal junction (GEJ)
•Patients must not have received treatment for metastatic or unresectable disease
•Patients must not have brain metastases
•Patients must have measurable and/or non-measurable disease
•Patients who have had HER-2 expression testing prior to patient consent to this study must be HER-2 negative; if HER-2 expression has not been tested prior to patient consent to this study, a second specimen must be submitted for HER-2 expression; if the specimen is HER-2 positive (or if HER-2 could not be evaluated), the patient will not be randomized
•Patients must have completed any prior neoadjuvant and adjuvant therapy for resectable disease at least 180 days prior to registration

CTSU S1115 - Details...

Selumetinib and Akt Inhibitor MK2206 or mFOLFOX Therapy Comprising Oxaliplatin and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer Previously Treated With Chemotherapy - Gastrointestinal Malignancies Stromal Tumors or GE Junction

This randomized phase II trial studies how well selumetinib and Akt inhibitor MK2206 work compared to mFOLFOX therapy in treating patients with metastatic pancreatic cancer previously treated with chemotherapy. Selumetinib and Akt inhibitor MK2206 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as oxaliplatin, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet know whether selumetinib and Akt inhibitor MK2206 are more effective than oxaliplatin and fluorouracil in treating patients with metastatic pancreatic cancer. Eligibility includes being at least 18 years old,

  • Patients must have histologically or cytologically confirmed diagnosis of pancreatic adenocarcinoma; patients with endocrine or neuroendocrine tumors, lymphoma of the pancreas, or ampullary cancer are not eligible
  • Patients must have distant metastatic disease; patients with macroscopic residual disease post-resection as the only site of disease are not eligible; patients must not have clinically significant ascites (defined as requiring paracentesis) or have brain metastases
  • Patients must have received one line, and no more than one line, of prior gemcitabine chemotherapy for pancreatic cancer; for patients who received treatment for advanced/metastatic disease, there must be documentation of disease progression while on this treatment; for patients who received chemotherapy for treatment in the adjuvant setting, recurrence to a metastatic site must be documented by imaging studies within 6months of completing chemotherapy

 

CTSU S 1201 - Details...

Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer - Gastrointestinal Malignancies Stromal Tumors or GE Junction

RATIONALE: Drugs used in chemotherapy, such as oxaliplatin, leucovorin calcium, fluorouracil, irinotecan hydrochloride, and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Combining more than one drug may kill more tumor cells. It is not yet known which regimen of combination chemotherapy is more effective in treating tumor cells.

PURPOSE: This randomized phase II trial studies how well oxaliplatin, leucovorin calcium, and fluorouracil work compared to irinotecan hydrochloride and docetaxel in treating patients with esophageal cancer, gastric cancer, or gastroesophageal junction cancer.

Eligibiltiy includes being at least 18 years old,

  • Patients must have unresectable advanced or metastatic histologically or cytologically confirmed adenocarcinoma of the esophagus, stomach, or gastroesophageal junction (GEJ)

    • Patients must not have received treatment for metastatic or unresectable disease
    • Patients must not have brain metastases

  • Patients must have measurable and/or non-measurable disease
  • Patients who have had HER-2 expression testing prior to patient consent to this study must be HER-2 negative; if HER-2 expression has not been tested prior to patient consent to this study, a second specimen must be submitted for HER-2 expression; if the specimen is HER-2 positive (or if HER-2 could not be evaluated), the patient will not be randomized
  • Patients must have completed any prior neoadjuvant and adjuvant therapy for resectable disease at least 180 days prior to registration

RTOG 1010 - Details...

Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer - Gastrointestinal Malignancies Stromal Tumors or GE Junction

Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as trastuzumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. It is not yet known whether giving radiation therapy and combination chemotherapy together with or without trastuzumab is more effective in treating esophageal cancer. This randomized phase III trial is studying how well giving radiation therapy, paclitaxel, and carboplatin together with or without trastuzumab works in treating patients with esophageal cancer. Eligibility includes being at least 18 years old, no previous chemotherapy, radiation or trastuzuman for esophageal cancer.

 

 

 

Pages